Anthocyanin supplementation in adults at risk for dementia: a randomized controlled trial on its cardiometabolic and anti-inflammatory biomarker effects

Simple item page
dc.contributor.authorBorda, Miguel Germán
dc.contributor.authorRamírez Vélez, Robinson
dc.contributor.authorBotero-Rodríguez, Felipe
dc.contributor.authorPatricio-Baldera, Jonathan
dc.contributor.authorLucia, Chiara de
dc.contributor.authorPola, Ilaria
dc.contributor.authorBarreto, George E.
dc.contributor.authorKhalifa, Khadija
dc.contributor.authorBergland, Anne Katrine
dc.contributor.authorKivipelto, Miia
dc.contributor.authorCederholm, Tommy
dc.contributor.authorZetterberg, Henrik
dc.contributor.authorAshton, Nicholas J.
dc.contributor.authorBallard, Clive
dc.contributor.authorSiow, Richard
dc.contributor.authorAarsland, Dag
dc.contributor.authorNJ FINGER
dc.contributor.departmentCiencias de la Saludes_ES
dc.contributor.departmentOsasun Zientziakeu
dc.date.accessioned2025-07-30T15:43:53Z
dc.date.available2025-07-30T15:43:53Z
dc.date.issued2025-05-02
dc.date.updated2025-07-30T15:30:07Z
dc.description.abstractAnthocyanins are dietary flavonoids shown to have a therapeutic capacity to mitigate inflammation and oxidative stress. The present secondary analyses from the “Anthocyanins in People at Risk for Dementia Study” were aimed at (I) determining the intervention’s effect on blood-based markers of cardiovascular disease and inflammation and (II) evaluating whether baseline factors such as age, sex, inflammation, or cardiometabolic score may moderate the intervention’s effect on inflammatory status. This study was an ancillary, 24-week randomized, double-blind, placebo-controlled Phase II trial. Sub-sample participants (n = 99), aged 60–80 years with mild cognitive impairment or cardiometabolic disorders, were randomized to receive either 320 mg/day of anthocyanins or placebo. The biomarkers analyzed included inflammatory biomarker assessment (IL − 6, IL − 8, IL − 10, IL − 1b, TNF − α, IFN − γ), and C-reactive protein (CRP), as well as albumin, thrombocytes, cholesterol, LDL, HDL, and triglycerides, which were longitudinally compared between both groups. Baseline characteristics were balanced between the groups. ANCOVA analyses reveal 24-week differences favoring the anthocyanin treatment in LDL cholesterol levels (ƞp2 = 0.078; p = 0.015), cardiometabolic score (ƞp2 = 0.073; p = 0.021), CRP levels (ƞp2 = 0.417; p = 0.0001), IL − 6 (ƞp2 = 0.085; p = 0.015), IL − 1b (ƞp2 = 0.058; p = 0.037), and Inflam z-score 5 (ƞp2 = 0.059, p = 0.004). Moderation analysis demonstrated that the inflammatory score at baseline was a significant predictor of the effect of the intervention on the CRP levels. Anthocyanin supplementation reduces CRP and cardiovascular disease biomarkers in individuals at risk of dementia, especially when there is increased inflammation at baseline. ClinicalTrials.gov study identifier: NCT03419039.en
dc.description.sponsorshipOpen Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The study funding was provided by a grant from the Norwegian Health Association (Grant no. 7330). Also, funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London. This work was supported by NordForsk through the funding to Nordic-Japan multidomain interventions for healthy aging and prevention of dementia and disability, project number 119886.
dc.format.mimetypeapplication/pdf
dc.identifier.citationBorda, M. G., Ramírez-Vélez, R., Botero-Rodriguez, F., Patricio-Baldera, J., Lucia, C. de, Pola, I., Barreto, G. E., Khalifa, K., Bergland, A. K., Kivipelto, M., Cederholm, T., Zetterberg, H., Ashton, N. J., Ballard, C., Siow, R., Aarsland, D., NJ FINGER (2025) Anthocyanin supplementation in adults at risk for dementia: a randomized controlled trial on its cardiometabolic and anti-inflammatory biomarker effects. GeroScience, 1-14. https://doi.org/10.1007/s11357-025-01669-8.
dc.identifier.doi10.1007/s11357-025-01669-8
dc.identifier.issn2509-2715
dc.identifier.urihttps://academica-e.unavarra.es/handle/2454/54527
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofGeroScience (2025 ), 1-14
dc.relation.publisherversionhttps://doi.org/10.1007/s11357-025-01669-8
dc.rights© The Author(s) 2025. This article is licensed under a Creative Commons Attribution 4.0 International License.
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectInflammationen
dc.subjectInflammation mediatorsen
dc.subjectCytokinesen
dc.subjectAnthocyaninsen
dc.subjectClinical trialen
dc.subjectAgingen
dc.titleAnthocyanin supplementation in adults at risk for dementia: a randomized controlled trial on its cardiometabolic and anti-inflammatory biomarker effectsen
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication
relation.isAuthorOfPublicationd0c2c11e-01d0-46ff-93b4-36b11beaf269
relation.isAuthorOfPublication.latestForDiscoveryd0c2c11e-01d0-46ff-93b4-36b11beaf269

Files

Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
German_AnthocyaninSupplementation.pdf
Size:
865.71 KB
Format:
Adobe Portable Document Format
Download
Thumbnail Image
Name:
German_AnthocyaninSupplementation_MatCompl.pdf
Size:
218.5 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Artículos de revista DCS - OZS Aldizkari artikuluak
Artículos de revista - Aldizkari artikuluak